Log In
BCIQ
Print this Print this
 

Oncopore (LTX-315)

  Manage Alerts
Collapse Summary General Information
Company Lytix Biopharma A/S
DescriptionOncolytic peptide immunotherapy
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced metastatic tumors; Treat malignant tumors; Treat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/06/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today